company background image
PSTX

Poseida Therapeutics NasdaqGS:PSTX Stock Report

Last Price

US$2.50

Market Cap

US$156.8m

7D

13.6%

1Y

-71.6%

Updated

03 Jul, 2022

Data

Company Financials +
PSTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

PSTX Stock Overview

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs.

Poseida Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Poseida Therapeutics
Historical stock prices
Current Share PriceUS$2.50
52 Week HighUS$11.10
52 Week LowUS$1.82
Beta0
1 Month Change21.36%
3 Month Change-47.26%
1 Year Change-71.56%
3 Year Changen/a
5 Year Changen/a
Change since IPO-83.71%

Recent News & Updates

May 15
Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

It's been a sad week for Poseida Therapeutics, Inc. ( NASDAQ:PSTX ), who've watched their investment drop 12% to...

Shareholder Returns

PSTXUS BiotechsUS Market
7D13.6%0.07%-2.5%
1Y-71.6%-25.1%-21.2%

Return vs Industry: PSTX underperformed the US Biotechs industry which returned -25.1% over the past year.

Return vs Market: PSTX underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is PSTX's price volatile compared to industry and market?
PSTX volatility
PSTX Average Weekly Movement15.5%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.3%

Stable Share Price: PSTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: PSTX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2014283Mark Gergenhttps://www.poseida.com

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers.

Poseida Therapeutics Fundamentals Summary

How do Poseida Therapeutics's earnings and revenue compare to its market cap?
PSTX fundamental statistics
Market CapUS$156.76m
Earnings (TTM)-US$144.72m
Revenue (TTM)US$32.67m

4.8x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PSTX income statement (TTM)
RevenueUS$32.67m
Cost of RevenueUS$19.76m
Gross ProfitUS$12.92m
Other ExpensesUS$157.64m
Earnings-US$144.72m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.31
Gross Margin39.54%
Net Profit Margin-442.92%
Debt/Equity Ratio55.9%

How did PSTX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is PSTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PSTX?

Other financial metrics that can be useful for relative valuation.

PSTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2x
Enterprise Value/EBITDA-0.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does PSTX's PS Ratio compare to its peers?

PSTX PS Ratio vs Peers
The above table shows the PS ratio for PSTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average145.8x
INMB INmune Bio
463x-60.6%US$157.4m
JNCE Jounce Therapeutics
6.2x58.4%US$156.1m
SESN Sesen Bio
7.2x47.6%US$159.4m
OVID Ovid Therapeutics
106.7x60.2%US$154.2m
PSTX Poseida Therapeutics
4.8x9.4%US$156.8m

Price-To-Sales vs Peers: PSTX is good value based on its Price-To-Sales Ratio (4.8x) compared to the peer average (145.8x).


Price to Earnings Ratio vs Industry

How does PSTX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: PSTX is good value based on its Price-To-Sales Ratio (4.8x) compared to the US Biotechs industry average (13.2x)


Price to Sales Ratio vs Fair Ratio

What is PSTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PSTX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.8x
Fair PS Ratio2.9x

Price-To-Sales vs Fair Ratio: PSTX is expensive based on its Price-To-Sales Ratio (4.8x) compared to the estimated Fair Price-To-Sales Ratio (2.9x).


Share Price vs Fair Value

What is the Fair Price of PSTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PSTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PSTX's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PSTX's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Poseida Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-8.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PSTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PSTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PSTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PSTX's revenue (9.4% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: PSTX's revenue (9.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PSTX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Poseida Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-32.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PSTX is currently unprofitable.

Growing Profit Margin: PSTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PSTX is unprofitable, and losses have increased over the past 5 years at a rate of 32.9% per year.

Accelerating Growth: Unable to compare PSTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PSTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).


Return on Equity

High ROE: PSTX has a negative Return on Equity (-139.55%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Poseida Therapeutics's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PSTX's short term assets ($190.5M) exceed its short term liabilities ($43.9M).

Long Term Liabilities: PSTX's short term assets ($190.5M) exceed its long term liabilities ($100.5M).


Debt to Equity History and Analysis

Debt Level: PSTX has more cash than its total debt.

Reducing Debt: PSTX's debt to equity ratio has increased from 16.6% to 55.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PSTX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PSTX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 31.4% each year


Discover healthy companies

Dividend

What is Poseida Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PSTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PSTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PSTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PSTX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PSTX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Mark Gergen (59 yo)

0.42

Tenure

US$2,823,916

Compensation

Mr. Mark J. Gergen, J.D., has been Chief Executive Officer at Poseida Therapeutics, Inc. since February 01, 2022 and serves as its Director and served as Chief Business Officer of Poseida Therapeutics, Inc...


CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD2.82M) is above average for companies of similar size in the US market ($USD1.83M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PSTX's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: PSTX's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Poseida Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Poseida Therapeutics, Inc.
  • Ticker: PSTX
  • Exchange: NasdaqGS
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$156.762m
  • Shares outstanding: 62.70m
  • Website: https://www.poseida.com

Number of Employees


Location

  • Poseida Therapeutics, Inc.
  • 9390 Towne Centre Drive
  • Suite 200
  • San Diego
  • California
  • 92121
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/03 00:00
End of Day Share Price2022/07/01 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.